198 related articles for article (PubMed ID: 30777895)
21. Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Panageas KS; Iwamoto FM; Cloughesy TF; Aldape KD; Rivera AL; Eichler AF; Louis DN; Paleologos NA; Fisher BJ; Ashby LS; Cairncross JG; Roldán Urgoiti GB; Wen PY; Ligon KL; Schiff D; Robins HI; Rocque BG; Chamberlain MC; Mason WP; Weaver SA; Green RM; Kamar FG; Abrey LE; Deangelis LM; Jhanwar SC; Rosenblum MK; Lassman AB
Neuro Oncol; 2012 Jun; 14(6):761-7. PubMed ID: 22661585
[TBL] [Abstract][Full Text] [Related]
22. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
23. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
[TBL] [Abstract][Full Text] [Related]
24. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
25. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
26. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
Garton ALA; Kinslow CJ; Rae AI; Mehta A; Pannullo SC; Magge RS; Ramakrishna R; McKhann GM; Sisti MB; Bruce JN; Canoll P; Cheng SK; Sonabend AM; Wang TJC
J Neurosurg; 2020 May; 134(5):1357-1367. PubMed ID: 32384274
[TBL] [Abstract][Full Text] [Related]
27. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Jaeckle KA; Ballman KV; van den Bent M; Giannini C; Galanis E; Brown PD; Jenkins RB; Cairncross JG; Wick W; Weller M; Aldape KD; Dixon JG; Anderson SK; Cerhan JH; Wefel JS; Klein M; Grossman SA; Schiff D; Raizer JJ; Dhermain F; Nordstrom DG; Flynn PJ; Vogelbaum MA
Neuro Oncol; 2021 Mar; 23(3):457-467. PubMed ID: 32678879
[TBL] [Abstract][Full Text] [Related]
28. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
[TBL] [Abstract][Full Text] [Related]
29. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
30. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA; Messersmith H; Gatson NT; Hottinger AF; Lassman A; Morton J; Ney D; Nghiemphu PL; Olar A; Olson J; Perry J; Portnow J; Schiff D; Shannon A; Shih HA; Strowd R; van den Bent M; Ziu M; Blakeley J
J Clin Oncol; 2022 Feb; 40(4):403-426. PubMed ID: 34898238
[TBL] [Abstract][Full Text] [Related]
31. Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas.
Tang L; Deng L; Bai HX; Sun J; Neale N; Wu J; Wang Y; Chang K; Huang RY; Zhang PJ; Li X; Xiao B; Cao Y; Tao Y; Yang L
J Neurooncol; 2018 Sep; 139(3):563-571. PubMed ID: 29923053
[TBL] [Abstract][Full Text] [Related]
32. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
33. A multi-institutional analysis of clinical outcomes and patterns of care of 1p/19q codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy.
Lin AJ; Kane LT; Molitoris JK; Smith DR; Dahiya S; Badiyan SN; Wang TJC; Kruser TJ; Huang J
J Neurooncol; 2020 Jan; 146(1):121-130. PubMed ID: 31741234
[TBL] [Abstract][Full Text] [Related]
34. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
35. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
37. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.
Liu Y; Liu S; Li G; Li Y; Chen L; Feng J; Yang Y; Jiang T; Qiu X
Cancer; 2022 Mar; 128(5):1085-1092. PubMed ID: 34780673
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
[TBL] [Abstract][Full Text] [Related]
39. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
